Cargando…
Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy [Image: see text]
Immunotherapy targeting the Programmed Death (PD‐1) receptor/ligand (L) “checkpoint” rapidly gains ground in the treatment of many cancer types. To increase treatment scope and efficacy, predictive biomarkers and rational selection of co‐treatments are required. To meet these demands, we must unders...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453912/ https://www.ncbi.nlm.nih.gov/pubmed/34106465 http://dx.doi.org/10.1002/eji.202048994 |